DEP114

DEP114 is an investigational oral solution developed by the Brazilian pharmaceutical company EMS for the treatment of allergic rhinitis. It is currently in Phase 3 clinical development, with a primary focus on pediatric patients aged 6 to 11 years suffering from moderate to severe persistent allergic rhinitis. In a pivotal Phase 3 trial (NCT06272409), DEP114 is being evaluated for superiority against desloratadine oral solution, a standard H1-antihistamine, using the global improvement in nasal symptoms score as the primary efficacy endpoint. While the specific active ingredient and its exact mechanism of action have not been publicly disclosed by the developer, the product is positioned as a pharmacological intervention for chronic respiratory allergies in children and is formulated as a solution for oral administration.